Lip Cancer Market By Diagnosis Test 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Lip Cancer Market
Lip Cancer Market: By Diagnosis Test (computed tomography (CT) scan, MRI scan, positron emission tomography (PET) scan, chest X-ray, complete blood count (CBC)), By Causes (Smoking, Alcohol, human papillomavirus (HPV), Others), & By Region-Forecast (2016-2021)
Report Code : HCR 0291
Updated Date: 07 January, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Lip cancers are development of abnormal cells that grow out of control and form lesions or tumors on the lips. They are the most common type of oral cancers. These cancers develop in thin, flat cells — called squamous cells — that line the lips, mouth, tongue, cheeks, sinuses, throat, and hard and soft palates. Symptoms of lip cancer include soreness, lumps or pale colored ulcers in the mouth that are usually painless at first but may become painful with disease progression. According to the National Institute of Dental and Craniofacial Research, most cases of oral cancer are linked to tobacco use and heavy alcohol use apart from that sun exposure is also a major risk factor, especially for people who work outdoors since they are more likely to have prolonged sun exposure. Globally increasing awareness is expected to drive the demand for lip cancer treatment during the period of study.

Lip Cancer Market

Geographically North America dominated global lip cancer market, due to higher awareness amongst its citizens advanced health care infrastructure, and technological advancement. North America was followed by Europe and Asia-Pacific as second and third largest market respectively. Asia Pacific is projected to have fastest growth, owing to rapidly increasing awareness, developing healthcare infrastructure and increasing spending on healthcare in developing nations such as China, and India in this region.

This report identifies the global lip cancer market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global lip cancer market.

This report segments global lip cancer market on the basis of diagnosis test, causes and regional market as follows:
  • Lip Cancer Market, By Diagnosis tests: computed tomography (CT) scan, MRI scan, positron emission tomography (PET) scan, chest X-ray, complete blood count (CBC))
  • The report has focused study on lip cancer market by basis of major causes such as: Smoking, Alcohol, human papillomavirus (HPV), Others
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the lip cancer market. Some of the major companies’ profiles in detail are as follows:
  • Astra Zeneca plc
  • Bristol Myers Squibb
  • Celgene
  • Eli Lilly & Co.
  • Hofmann La Roche
1. Lip Cancer Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Lip Cancer Market– Market Forces
   4.1. Drivers
      4.1.1. Increasing reported incidence of lip cancer globally
      4.1.2. Increasing awareness about lip cancer in developing economies
   4.2. Restraints
      4.2.1. Higher cost of research and development
   4.3. Opportunities
      4.3.1. Emerging economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Lip Cancer Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Lip Cancer Market, By Diagnosis Test
   6.1. computed tomography (CT) scan
   6.2. MRI scan
   6.3. positron emission tomography (PET) scan
   6.4. chest X-ray
   6.5. complete blood count (CBC)
   6.6. Others 
7. Lip Cancer Market, By Causes
   7.1. Smoking
   7.2. Alcohol
   7.3. human papillomavirus (HPV)
   7.4. Others
8. Lip Cancer Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Lip Cancer – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   10.1. Astra Zeneca plc
   10.2. Bristol Myers Squibb
   10.3. Celgene
   10.4. Eli Lilly & Co.
   10.5. Hofmann La Roche
   10.6. Pfizer
   10.7. Sanofi Aventis
   10.8. Teva Pharmaceuticals
   10.9. Novartis AG
   10.10. Cipla.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports